|
Published by: Freedonia Group Inc
Published: Mar. 1, 2008 - 338 Pages
Table of Contents
- INTRODUCTION
- I. EXECUTIVE SUMMARY
- II. MARKET ENVIRONMENT
- General
- Macroeconomic Trends
- Demographic Patterns
- Health Care Trends
- Health Insurance
- Medical Conditions
- Acute Conditions
- Chronic Conditions
- National Health Expenditures
- Medical Providers
- Outpatient Clinics
- Skilled Nursing Homes
- Acute Care Hospitals
- Physicians
- Patient Activity
- Acute Care Hospital Admissions
- Surgical Procedures
- Outpatient Visits
- Pharmaceutical Market Overview
- Regulation
- Research & Development
- Demand Patterns & Forecasts
- Therapeutic Classes
- Generic Competition
- Dosage Formulations
- Regulatory Classifications
- III. DRUG DELIVERY MATERIALS
- General
- Sterile & Purified Water
- Synthetic Polymers
- Polyethylene Glycol (PEG)
- Acrylic Polymers
- Carbomers
- Methacrylate Copolymers
- Polyethylene Oxide
- Polyvinyl Alcohol
- Other Synthetic Polymers
- Cellulose Derivatives
- Ethyl Cellulose
- Hydroxypropyl Methylcellulose (HPMC)
- Other Cellulose Derivatives
- Minerals
- Mineral Hydrocarbons
- Petrolatum
- Mineral Oil
- Mineral Hydrocarbon Waxes
- Other Minerals
- Attapulgite
- Calcium Carbonate
- Calcium Silicate
- Electrolytes
- Other Drug Delivery Materials
- Starch Compounds
- Cyclodextrins
- Dextrates
- Dextrin
- Maltodextrin
- Sugars & Polyols
- Sucrose
- Sorbitol
- Lactose
- Mannitol
- Natural Gums
- All Other Drug Delivery Materials
- IV. DRUG DELIVERY SYSTEMS OVERVIEW
- General
- Types of Drug Delivery Systems
- Historical Demand Patterns
- Regulation
- Research & Development
- US Trade
- International Markets
- V. ORAL DRUG DELIVERY SYSTEMS
- General
- Controlled-Release Formulations
- Technologies
- Coated Systems
- Diffusion Systems
- Reservoir Systems
- Chewable Tablets
- Orally Disintegrating Tablets
- Nanoparticulate Formulations
- Ethical Pharmaceuticals
- Over-the-Counter Drugs
- Transmucosal Formulations
- VI. PARENTERAL DRUG DELIVERY SYSTEMS
- General
- Therapeutic Monoclonal Antibodies
- Technology
- Anti-Cancer Agents
- Other Therapeutic Monoclonal Antibodies
- Products in Development
- Prefilled Syringes
- Applications
- Injectors
- Cartridges & Insulin Pens
- Encapsulated Systems
- Polymer-Protected Systems
- PEGylated Formulations
- Other Polymer-Protected Pharmaceuticals
- Liposomes
- Developmental Activities
- Premixed IV Solutions
- Mini-Bags
- Bag/Vial Infusion Systems
- Applications
- VII. INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS
- General
- Inhalation Drug Delivery Systems
- Dry Powder Formulations
- Devices & Technologies
- Applications
- Metered Dose Formulations
- Devices & Technologies
- Applications
- Transdermal Drug Delivery Systems
- Products & Technologies
- Developers & Suppliers
- Applications
- Implantable Drug Delivery Systems
- Drug-Eluting Stents
- Drug Inserts
- Brachytherapy
- VIII. APPLICATIONS
- General
- Central Nervous System Agents
- Respiratory Agents
- Hormones & Related Agents
- Gastrointestinal Agents
- Cardiovascular Agents
- Anti-Infective Agents
- Nutritional Agents
- Biologicals
- Genito-Urinary Agents
- Other Therapies
- IX. INDUSTRY STRUCTURE
- General
- Developmental Revenues
- Market Share
- Competitive Strategies
- Mergers & Acquisitions
- Licensing & Related Agreements
- Marketing & Distribution
- Manufacturing
- Company Profiles
- Alkermes Incorporated
- AptarGroup Incorporated
- Aradigm Corporation
- Associated British Foods plc
- Aveva Drug Delivery Systems, see Nitto Denko
- Baxter International Incorporated
- Becton, Dickinson and Company
- Bespak, see Consort Medical
- Cardinal Health Pharmaceutical Technologies and Services, see Catalent Pharma Solutions
- Catalent Pharma Solutions Incorporated
- Cephalon Incorporated
- CIMA LABS, see Cephalon
- Consort Medical plc
- Corium International Incorporated
- CyDex Pharmaceuticals Incorporated
- Depomed Incorporated
- Dow Corning Corporation
- DURECT Corporation
- Elan Corporation plc
- Emisphere Technologies Incorporated
- Encore Medical, see ReAble Therapeutics
- Eurand NV
- Flamel Technologies SA
- Genzyme Corporation
- Hospira Incorporated
- IOMED, see ReAble Therapeutics
- Johnson & Johnson
- Nastech Pharmaceutical Company Incorporated
- Nektar Therapeutics
- Nitto Denko Corporation
- NOF Corporation
- Penwest Pharmaceuticals Company
- ReAble Therapeutics Incorporated
- Safety Syringes Incorporated
- SPI Pharma, see Associated British Foods
- StrataGent Life Sciences, see Corium International
- 3M Company
- Valeritas LLC
- Valois SAS, see AptarGroup
- Other Companies Mentioned in Study
- LIST OF TABLES
- SECTION I -- EXECUTIVE SUMMARY
- Summary Table
- SECTION II -- MARKET ENVIRONMENT
- 1 Macroeconomic Indicators
- 2 Population by Age Group
- 3 Acute Conditions by Type
- 4 Chronic Conditions by Type
- 5 National Health Expenditures by Type
- 6 Medical Providers by Type
- 7 Patient Activity by Type
- 8 Pharmaceutical Demand by Therapeutic Class
- 9 Pharmaceutical Demand by Commercial Status
- 10 Pharmaceutical Demand by Dosage Formulation
- 11 Pharmaceutical Demand by Regulatory Classification
- SECTION III -- DRUG DELIVERY MATERIALS
- 1 Drug Delivery Material Demand by Type
- 2 Sterile & Purified Water Demand in Drug Delivery
- 3 Synthetic Polymer Demand in Drug Delivery
- 4 Cellulose Derivative Demand in Drug Delivery
- 5 Mineral Demand in Drug Delivery
- 6 Other Material Demand in Drug Delivery
- SECTION IV -- DRUG DELIVERY SYSTEMS OVERVIEW
- 1 Drug Delivery System Demand by Dosage Formulation
- 2 Drug Delivery System Demand, 1997-2007
- 3 US Trade in Drug Delivery Systems
- 4 World Drug Delivery System Demand by Region
- SECTION V -- ORAL DRUG DELIVERY SYSTEMS
- 1 Oral Drug Delivery System Demand by Type
- 2 Oral Controlled-Release Drug Delivery System Demand
- 3 Coated Controlled-Release Drug Delivery System Demand
- 4 Diffusion Controlled-Release Drug Delivery System Demand
- 5 Reservoir Controlled-Release Drug Delivery System Demand
- 6 Chewable Tablet Demand by Therapeutic Class
- 7 Orally Disintegrating Tablet Demand by Therapeutic Class
- 8 Nanoparticulate Oral Drug Delivery System Demand by Therapeutic Class
- 9 Oral Transmucosal Drug Delivery System Demand by Therapeutic Class
- SECTION VI -- PARENTERAL DRUG DELIVERY SYSTEMS
- 1 Parenteral Drug Delivery System Demand by Type
- 2 Therapeutic Monoclonal Antibody Demand by Therapeutic Class
- 3 Therapeutic Monoclonal Antibodies Approved for US Sale
- 4 Prefilled Syringe Demand by Therapeutic Class
- 5 Encapsulated Parenteral Drug Delivery System Demand by Type & Therapeutic Class
- 6 Premixed IV Solution Demand by Therapeutic Class
- SECTION VII -- INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS
- 1 Other Drug Delivery System Demand by Type
- 2 Inhalation Drug Delivery System Demand by Type & Therapeutic Class
- 3 Transdermal Drug Delivery System Demand by Therapeutic Class
- 4 Implantable Drug Delivery System Demand by Type & Therapeutic Class
- SECTION VIII -- APPLICATIONS
- 1 Drug Delivery System Demand by Therapeutic Class
- 2 Central Nervous System Drug Delivery Demand by Type
- 3 Respiratory Drug Delivery Demand by Type
- 4 Hormone & Related Drug Delivery Demand by Type
- 5 Gastrointestinal Drug Delivery System Demand by Type
- 6 Cardiovascular Drug Delivery System Demand by Type
- 7 Anti-Infective Drug Delivery System Demand by Type
- 8 Nutritional Delivery System Demand by Type
- 9 Biological Delivery System Demand by Type
- 10 Genito-Urinary Drug Delivery System Demand
- 11 Drug Delivery System Demand in Other Therapies
- SECTION IX -- INDUSTRY STRUCTURE
- 1 Drug Delivery Revenues by Company, 2007
- 2 Selected Acquisitions & Divestitures
- 3 Selected Cooperative Agreements
- LIST OF CHARTS
- SECTION III -- DRUG DELIVERY MATERIALS
- 1 Drug Delivery Material Demand by Type, 2007
- SECTION IV -- DRUG DELIVERY SYSTEMS OVERVIEW
- 1 Drug Delivery System Demand by Dosage Formulation, 2007
- SECTION V -- ORAL DRUG DELIVERY SYSTEMS
- 1 Oral Drug Delivery System Demand by Type, 2007
- SECTION VI -- PARENTERAL DRUG DELIVERY SYSTEMS
- 1 Parenteral Drug Delivery System Demand by Type, 2007
- SECTION VII -- INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS
- 1 Inhalation, Transdermal & Implantable Drug Delivery
- System Demand by Type, 2007
- SECTION VIII -- APPLICATIONS
- 1 Drug Delivery System Demand by Therapeutic Class, 2007
- SECTION IX -- INDUSTRY STRUCTURE
- 1 US Drug Delivery Product Sales by Company, 2007
AbstractDemand to grow more than 10% annually through 2012
US demand for drug delivery systems is projected to expand more than ten percent annually to $132 billion in 2012. Growth opportunities for drug delivery systems extend into all therapeutic classes of pharmaceuticals and encompass a wide range of compounds and formulations. Central nervous system, respiratory and hormone and related agents will remain the top three applications based on the special formulating needs of medicines for conditions such as arthritis, multiple sclerosis, asthma, allergies and cancer. However, favorable growth opportunities will emerge for drug delivery systems in most other therapeutic classes due to safety and efficacy shortcomings in many conventional medicines.
Please Note: Freedonia requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
